Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2006 1
2007 2
2009 2
2012 1
2015 1
2017 1
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Clinical Trial.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
APOE and AGT in the Finnish p.Arg133Cys CADASIL population.
Siitonen M, Mykkänen K, Pescini F, Rovio S, Kääriäinen H, Baumann M, Pöyhönen M, Viitanen M. Siitonen M, et al. Among authors: mykkanen k. Acta Neurol Scand. 2015 Dec;132(6):430-4. doi: 10.1111/ane.12400. Epub 2015 Mar 26. Acta Neurol Scand. 2015. PMID: 25819272
Detection of the founder effect in Finnish CADASIL families.
Mykkänen K, Savontaus ML, Juvonen V, Sistonen P, Tuisku S, Tuominen S, Penttinen M, Lundkvist J, Viitanen M, Kalimo H, Pöyhönen M. Mykkänen K, et al. Eur J Hum Genet. 2004 Oct;12(10):813-9. doi: 10.1038/sj.ejhg.5201221. Eur J Hum Genet. 2004. PMID: 15378071
Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients.
Tikka S, Mykkänen K, Ruchoux MM, Bergholm R, Junna M, Pöyhönen M, Yki-Järvinen H, Joutel A, Viitanen M, Baumann M, Kalimo H. Tikka S, et al. Among authors: mykkanen k. Brain. 2009 Apr;132(Pt 4):933-9. doi: 10.1093/brain/awn364. Epub 2009 Jan 27. Brain. 2009. PMID: 19174371 Free PMC article.
CADASIL mutations and shRNA silencing of NOTCH3 affect actin organization in cultured vascular smooth muscle cells.
Tikka S, Ng YP, Di Maio G, Mykkänen K, Siitonen M, Lepikhova T, Pöyhönen M, Viitanen M, Virtanen I, Kalimo H, Baumann M. Tikka S, et al. Among authors: mykkanen k. J Cereb Blood Flow Metab. 2012 Dec;32(12):2171-80. doi: 10.1038/jcbfm.2012.123. Epub 2012 Sep 5. J Cereb Blood Flow Metab. 2012. PMID: 22948298 Free PMC article. Clinical Trial.
Mitochondrial DNA sequence variation and mutation rate in patients with CADASIL.
Annunen-Rasila J, Finnilä S, Mykkänen K, Moilanen JS, Veijola J, Pöyhönen M, Viitanen M, Kalimo H, Majamaa K. Annunen-Rasila J, et al. Among authors: mykkanen k. Neurogenetics. 2006 Jul;7(3):185-94. doi: 10.1007/s10048-006-0049-x. Epub 2006 Jun 29. Neurogenetics. 2006. PMID: 16807713
Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient.
Ihalainen S, Soliymani R, Iivanainen E, Mykkänen K, Sainio A, Pöyhönen M, Elenius K, Järveläinen H, Viitanen M, Kalimo H, Baumann M. Ihalainen S, et al. Among authors: mykkanen k. Mol Med. 2007 May-Jun;13(5-6):305-14. doi: 10.2119/2006–00069.Ihalainen. Mol Med. 2007. PMID: 17622327 Free PMC article.
12 results